Goodwin Procter LLP and Wilson Sonsini Goodrich & Rosati advised MBX Biosciences on the deal.
MBX Biosciences closed its $34.6 million Series A financing.
The financing was led by Frazier Healthcare Partners, with participation from OrbiMed, New Enterprise Associates, Indiana Philanthropic Venture Fund (IU PhV), Indiana Seed Fund III (managed by BioCrossroads) and Twilight Venture Partners II.
The company intends to use the funds to advance its preclinical pipeline of peptide therapeutic candidates directed at clinically validated molecular targets.
MBX Biosciences is a biotechnology company creating therapies for rare endocrine diseases. Members of MBX’s leadership team previously collaborated in the creation of highly successful endocrine drugs (Humalog®, Forteo®) and three Indiana-based companies (Marcadia, Calibrium and MB2). MBX is strengthened by world-class proprietary technology and drug candidates licensed from the DiMarchi Indiana University laboratory. The company is supported by investment from leading life science investors that include Frazier Healthcare Partners, OrbiMed, and New Enterprise Associates.
The Goodwin team was led by Mitch Bloom (Picture), Kristin Gerber, Dan Hughes, and Matthew Rosencranz.
The Wilson Sonsini Goodrich & Rosati team included Kenneth Clark, Marina Tsatalis, Michael Hostetler, Sean Reed and Uale Taotafa.
Involved fees earner: Mitchell Bloom – Goodwin Procter; Kristin Gerber – Goodwin Procter; Daniel Hughes – Goodwin Procter; Matthew Rosencranz – Goodwin Procter; Kenneth Clark – Wilson Sonsini Goodrich & Rosati; Michael Hostetler – Wilson Sonsini Goodrich & Rosati; Sean Reed – Wilson Sonsini Goodrich & Rosati; Uale Taotafa – Wilson Sonsini Goodrich & Rosati; Marina Tsatalis – Wilson Sonsini Goodrich & Rosati;
Clients: MBX Biosciences Inc.;